What Is DSIP?
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nine-amino-acid (nonapeptide) regulatory peptide with a molecular weight of 848.8 Da. It exists in two forms: a free peptide and a phosphorylated form (pDSIP), with the latter having distinct pharmacokinetics and potentially different receptor interactions.
DSIP is widely distributed in the central nervous system — detected in the hypothalamus, limbic system, brainstem, and pituitary — as well as in peripheral tissues including the gut, plasma, and breast milk. Its broad distribution and multiple neuroendocrine effects suggest it functions as a pleiotropic regulatory peptide rather than a single-function sleep factor.
Discovery & Distribution
DSIP was discovered by Monnier and Schoenenberger (1977) at the University of Basel. The original experiments showed that thalamic venous blood collected from sleeping rabbits, when infused into alert recipient rabbits, induced sleep — particularly slow-wave (delta) sleep characterised by high-amplitude, low-frequency EEG oscillations. The active factor was isolated and named Delta Sleep Inducing Peptide.
DSIP has been detected by radioimmunoassay and immunohistochemistry in:
- CNS: Hypothalamus (highest concentration), limbic system, brainstem raphe nuclei, cerebellum, pituitary portal blood
- Peripheral: Plasma (0.2–0.5 nM range), GI tract neurons, adrenal gland, breast milk, colostrum
- Circadian rhythm: Plasma DSIP shows circadian variation, peaking during early sleep phases in humans
Sleep Effects
The original and most replicated finding with DSIP is its effect on sleep architecture, specifically the promotion of non-REM slow-wave sleep (SWS, NREM stages 3–4):
EEG studies show ↑ delta power (0.5–4 Hz) following DSIP administration — the hallmark of deep, restorative sleep
Reduced time to sleep onset in some rodent models; effect is dose-dependent and species-specific
DSIP may help align sleep timing with circadian phase — relevant in jet lag and shift-work disruption models
Unlike benzodiazepines, DSIP does not suppress REM sleep — important distinction for sleep quality research
A key differentiator from pharmacological sleep aids (benzodiazepines, Z-drugs) is that DSIP promotes physiological slow-wave sleep without suppressing REM sleep or producing post-sleep cognitive impairment in animal models. This profile makes it a research tool for studying natural sleep architecture rather than pharmacologically-induced sedation.
Neuroendocrine Modulation
DSIP exerts multiple neuroendocrine effects beyond sleep regulation:
Cortisol / HPA Axis
DSIP inhibits the hypothalamic-pituitary-adrenal (HPA) axis in stress conditions, reducing corticotropin (ACTH) and cortisol secretion. This anti-stress hormonal modulation is consistent with its proposed role as a general stress-buffer. In clinical studies of opiate withdrawal, DSIP significantly reduced ACTH/cortisol elevation and associated withdrawal symptoms.
LH & Reproductive Axis
DSIP modulates luteinising hormone (LH) pulsatility. Administration reduces LH pulse amplitude in some models while maintaining pulsatile pattern — suggesting a fine-tuning role in HPG axis regulation rather than suppression.
GH Release
Consistent with its sleep-promoting effect (GH is secreted primarily during SWS), DSIP has been shown to increase GH release in some studies — likely an indirect effect mediated through enhanced SWS rather than direct GH secretagogue activity.
Stress Buffering & Neuroprotection
A body of Soviet/Russian research from the 1980s–1990s (which remains less cited in Western literature but is internally consistent) documents DSIP's anti-stress effects:
- Stress ulcer protection: DSIP reduced gastric ulcer formation in restrained rodents (Selye stress model), suggesting HPA axis buffering with peripheral GI-protective effects
- Opiate withdrawal: IV DSIP in human opiate-dependent subjects reduced withdrawal symptom severity (rated by clinical scales) compared to placebo — one of the few human clinical findings with DSIP
- Oxidative stress: In vitro data suggests DSIP has antioxidant properties, though mechanism is unclear (possibly via Trp-containing radical scavenging chemistry)
- Oncostatic research: Early data from Russian cancer biology groups suggested DSIP reduced tumour growth rates in some carcinoma models; significance and mechanism remain unconfirmed
Mechanism Research — Open Questions
Despite 45+ years of research, DSIP's definitive receptor has not been identified. This is unusual for a well-studied bioactive peptide and represents the central open question in DSIP research. Current hypotheses include:
- Interaction with adenosine receptors: Adenosine is a key endogenous sleep-promoting molecule; DSIP may modulate adenosinergic signalling in the basal forebrain
- GABA-A modulation: DSIP may potentiate GABA-A receptor function at sleep-regulatory circuits in the hypothalamus and brainstem
- Prostaglandin D₂ pathway: PGD₂ is a potent endogenous sleep factor; DSIP may interact with this pathway
- Opioid receptor interaction: Some data suggests weak interactions with opioid receptors — consistent with its effects on withdrawal and stress
DSIP receptor identification has been challenging due to: (1) its very low plasma concentrations (sub-nanomolar), making high-affinity binding studies technically demanding; (2) rapid plasma degradation; and (3) multiple possible conformations in solution. Modern proteomics and cryo-EM approaches are being applied to resolve this.
Research Protocols
Sleep Architecture (EEG)
- Model: Chronically implanted EEG/EMG rats
- Dose: 30–100 nmol/kg IV or ICV (intracerebroventricular)
- Timing: 1h before expected sleep onset
- Endpoints: % time in SWS, delta power spectral density, REM%
Stress Response Studies
- Model: Restraint stress (2h) or CRS (chronic restraint stress)
- Dose: 100 µg/kg SC or IP × 7–14 days
- Endpoints: Serum corticosterone, adrenal weight, ulcer scoring
- Controls: Vehicle, metyrapone (corticosterone synthesis inhibitor)
Circadian Rhythm Research
- Model: Jetlag-shifted mice (6h light cycle advance)
- Treatment: DSIP at CT12 (subjective dusk)
- Endpoints: Re-entrainment rate (days to stable activity rhythm), sleep timing
- Compare: Vehicle, melatonin positive control
FAQ
What is DSIP?
A naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from sleeping rabbit thalamic blood in 1977. It promotes slow-wave sleep, modulates cortisol and LH, and buffers stress responses in preclinical models.
Does DSIP actually induce delta sleep?
The original transfer experiments and EEG studies in rodents confirm DSIP increases delta (slow-wave) sleep power. However, the receptor mediating these effects has not been definitively identified, making the full mechanistic picture incomplete.
How does DSIP differ from sleep drugs like benzodiazepines?
DSIP promotes physiological slow-wave sleep without suppressing REM sleep or producing post-sleep cognitive impairment in animal models. Benzodiazepines suppress both SWS and REM and typically impair the restorative quality of sleep architecture despite reducing sleep latency.
What is the phosphorylated form (pDSIP)?
Phospho-DSIP (pDSIP) has a phosphate group on the Ser residue. It has longer plasma half-life and may have distinct receptor binding properties. Some research suggests pDSIP has different sleep-modulatory effects than the free peptide form.
DSIP for Research
Lyophilised DSIP ≥98% purity (HPLC), free peptide form, with full COA and mass spec verification.
View DSIP →